Skip to main content
Clinical Trials/NCT00771355
NCT00771355
Terminated
Not Applicable

In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

Massachusetts General Hospital1 site in 1 country40 target enrollmentAugust 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vitiligo
Sponsor
Massachusetts General Hospital
Enrollment
40
Locations
1
Primary Endpoint
To describe characteristic features seen by confocal microscopy of several pigmentary disorders.
Status
Terminated
Last Updated
15 years ago

Overview

Brief Summary

This is a pilot study to evaluate the findings of the Reflectance Confocal Microscopy when performed in cutaneous pigmentary disorders, such as vitiligo, melasma, post-inflammatory hyper-pigmentation and hypo-pigmentation. Confocal Microscopy is a recent diagnostic technique that has been used for observation of skin conditions that affect the superficial layers of the skin.

Registry
clinicaltrials.gov
Start Date
August 2008
End Date
July 2010
Last Updated
15 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects 20-70 years of age.
  • Clinical diagnosis of vitiligo, melasma, post-inflammatory hypo or depigmentation or post-inflammatory hyperpigmentation.
  • Willing and able to understand and sign informed consent.
  • Able to complete study and comply with study procedures.

Exclusion Criteria

  • Use of topical therapies such as corticosteroids, protopic, hydroquinone and azelaic acid within the past 2 months.
  • Use of light therapy such as narrow-band-UVB, PUVA or laser within the past 2 months.
  • Intake of medications that can cause pigmentary changes within the past year. Examples are:
  • Antimalarials (chloroquine, hydroxychloroquine)
  • Chemotherapeutics (bleomycin, busulfan, doxorubicin, daunorubicin, fluorouracil, cyclophosphamide, and carmustine)
  • Heavy metals (gold, silver, bismuth, and mercury)
  • Tetracyclines (including minocycline, doxycycline)
  • Amiodarone
  • Azidothymidine
  • Clofazimine

Outcomes

Primary Outcomes

To describe characteristic features seen by confocal microscopy of several pigmentary disorders.

Time Frame: study visit

Study Sites (1)

Loading locations...

Similar Trials